We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > STOP 301

News List

Impel NeuroPharma Announces NDA Acceptance of INP104 for Acute Migraine americanpharmaceuticalreview
January 25, 2021
Impel NeuroPharma announced the U.S. Food and Drug Administration (FDA) has accepted for review the company's 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults.
Impel NeuroPharma Announces Positive Results from Acute Migraine Treatment Trial americanpharmaceuticalreview
June 22, 2020
Impel NeuroPharma announced positive results from "STOP 301" (Safety and Tolerability of POD-DHE), the Company's pivotal Phase 3, open-label study of the safety and tolerability of INP104 (dihydroergotamine mesylate) or DHE ...